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Lipodystrophy is a well-recognised adverse effect of HIV and antiretroviral therapy, with certain antiretrovirals, specifically 
thymidine analogues, implicated in the aetiology and pathogenesis. Lipodystrophy is often accompanied by metabolic 
complications, such as hyperlipidaemia and insulin resistance, which increase risk for cardiovascular disease. There are limited 
data on the effect of treatment modification, pharmacological interventions and surgical management on this condition. 
Here we summarise the latest data on lipodystrophy, with the aim of facilitating informed decision-making in managing this 
condition. In light of the absence of cost-effective measures to treat lipoatrophy and lipohypertrophy, prevention remains the 
best option; we recommend targeted annual screening. Healthcare workers should be sensitised to early detection in patients 
on thymidine-based regimens, and affected patients should be switched to an appropriate regimen as soon as feasible. There 
is no evidence to support the use of new-generation ARVs, except in patients with significant hypercholesterolaemia, where 
atazanavir and raltegravir may present better options. 
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The lipodystrophy syndrome is a well-recognised phenomenon 
in HIV-1-infected patients receiving antiretroviral therapy 
(ART). The syndrome is characterised by body habitus changes, 
most commonly a combination of lipoatrophy (LA) (loss of 
peripheral subcutaneous adipose tissue (SAT), usually in the 
face, limbs and buttocks) and lipohypertrophy (LH) (visceral 
adipose tissue (VAT) accumulation, gynaecomastia and, in 
some cases, lipomatosis, especially in the dorsocervical area, 
known as a ‘buffalo hump’). 
Even though the aetiology remains unclear, the following 
factors have been implicated in the development of lipodystrophy: 
HIV itself, older age, female sex, genetic parameters and ART. [1] 
There seems to be consensus that peripheral LA and central 
LH have the same causes (HIV and ART), but are likely to be 
related to different fat depot physiologies.[2] It is speculated that 
LA is linked to severe mitochondrial dysfunction, oxidative 
stress and inflammation, while hypertrophy is related to mild 
mitochondrial dysfunction and cortisol activation, promoted 
by inflammation. Importantly, both LA in the lower part 
of the body and abdominal LH have been associated with 
metabolic changes akin to the metabolic syndrome, particularly 
dyslipidaemia and insulin resistance.[3]
Recent reports in the popular press have highlighted the 
psychological and social distress that patients experience as a 
result of lipodystrophy. Often, patients are left on offending 
regimens for too long, causing extreme and often irreversible 
body changes. It is imperative that healthcare workers 
familiarise themselves with this entity and understand the 
treatment options available to patients. Here we summarise the 
latest data on the topic, with the aim of facilitating informed 
decision-making in managing this condition.
Role of ART
Data on the effect of ART on lipodystrophy exist for the older 
nucleoside reverse transcriptase inhibitors (NRTIs) and unboosted 
protease inhibitors (PIs), but seem to be conflicting for the 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 
newer PIs, and are mostly unavailable for the new drug classes. 
Many studies have implicated stavudine (d4T) and zidovudine 
(AZT) in the development of lipodystrophy and this is generally 
uncontested. Abacavir (ABC) and tenofovir (TDF) have been 
shown to have minimal effect.[6] Initial studies did not reveal a 
role for efavirenz (EFV) in lipodystrophy, but the recent ACTG 
A5142 study[6] found that LA was indeed more relevant in EFV-
treated patients when compared with boosted lopinavir (LPV/r)-
treated patients. Another study, however, found only a minimal 
difference between EFV and another PI, atazanavir (ATV).[7] Taken 
together, these studies suggest that in terms of the development of 
LA, LPV may have a slight advantage over EFV when combined 
with TDF (up to 96 weeks) in treatment-naive patients. In terms 
of lipodystrophy, ATV may have a marginal advantage over EFV 






















patients. Importantly, ATV is known to have a better lipid profile than EFV 
and LPV/r and an argument could therefore be made for its preferential use 
in patients at high risk for cardiovascular disease. 
The 2011 United States Department of Health and Human Services 
ART guidelines state that an increase in trunk fat has been observed 
with EFV-, PI-, and raltegravir (RAL)-containing regimens, but that a 
causal relationship has not been established.[4] There are very few data 
on the entry inhibitors and integrase inhibitors, although some early 
data indicate the possibility of an improved metabolic and lipid profile. 
There are currently no systematic reviews or meta-analyses comparing 
the effects of different antiretrovirals (ARVs) on lipodystrophy. The 
comparison of studies is complicated by different measurement 
standards for lipodystrophy, the use of different race and ethnic groups, 
and a general lack of control groups. 
Table 1 summarises the current knowledge about the effect of 
different ARVs on lipodystrophy, lipids and glucose metabolism. 
It is important to note that the number of patients changing ART 
regimens because of lipodystrophy appears to be decreasing over time. 
The Swiss HIV Cohort Study[5]  followed 5 777 participants who started 
ART between 2000 and 2006, and compared rates of lipodystrophy 
between 2000 and 2002, and 2003 and 2006. The findings revealed that 
4% of patients had changed ART regimens due to lipodystrophy during 
2000 - 2002, whereas only 1% of patients changed during 2003 - 2006. This 
reduction was attributed to the decreased use of AZT (88% v. 64%) and d4T 
(4.2% v. 0.7%) and the increased use of TDF (0% v. 30%) over this time.[5] 
The differential metabolic effects of the NNRTIs, NRTIs and PIs are 
depicted in Fig. 1. There is currently not enough long-term information 
on entry inhibitors and integrase inhibitors to allow for categorisation.
Metabolic consequences of 
lipodystrophy
Lipodystrophy is well known to cause significant psychological distress 
and has been identified as a risk factor for ART non-adherence.[9,10] 
There are, however, other consequences that may warrant treatment 
modification, especially metabolic complications. Fig. 2 shows that 
increased central fat and decreased limb fat are implicated in the 
development of metabolic complications. The basic pathology is 
postulated to be an increased release of cytokines and free fatty acids 
(FFAs) which, together with decreased adiponectin production by 
adipose tissue, lead to insulin resistance and triglyceride (TG) deposition 
in tissues such as the liver, skeletal muscle and heart. It seems that active 
lipolysis in SAT, combined with impaired fat storage capacity in the 
subcutaneous depot, drives the deposition of lipids in ectopic sites such 
as the viscera and other non-adipose sites. This leads to hepatic steatosis 
and increased lipid content in skeletal muscle, which contribute to 
systemic metabolic alterations, especially insulin resistance. The high 
levels of FFAs may also affect pancreatic function and thus contribute to 
impaired insulin release and a pre-diabetic  state. 
These metabolic changes ultimately result in impaired glucose 
tolerance and dyslipidaemia with decreased high-density lipoprotein 
cholesterol (HDL-C) and increased TGs. Metabolic complications are 
therefore responsible for increased cardiovascular and hepatic disease 
risks. These changes have also been linked to premature ageing. The 
hypothesis has been put forward that chronic HIV infection, combined 
with the use of some ARVs and lipodystrophy, may accelerate the 
normal ageing processes and lead to the early development of age-
related co-morbidities.[2]
Table 1. The effects of different ARV drugs on fat and metabolism*
Drug LA LH Dyslipidaemia Insulin resistance
Stavudine (d4T) +++ ++ ++ ++
Zidovudine (AZT) ++ + + ++
Didanosine (DDI) +/- +/- + +
Lamivudine (3TC) 0 0 + 0
Abacavir (ABC) 0 0 + 0
Tenofovir (TDF) 0 0 0 0
Emtricitabine (FTC) 0 0 0 0
Efavirenz (EFV) +/- +/- ++ HDL + 
Nevirapine (NVP) 0 0 + HDL 0
Ritonavir (RTV) +/- + +++ ++
Indinavir (IDV) +/- + + +++
Lopinavir (LPV) +/- + ++ ++
Saquinavir (SQV) +/- + +/- +/-
Atazanavir (ATV) 0 ++ +/- 0
Darunavir (DRV) 0 + +/- +/-
Enfuvirtide (INN) Insufficient data Insufficient data 0 0
Maraviroc (MVC) Insufficient data Insufficient data 0 0
Raltegravir (RAL) Insufficient data Insufficient data 0 0
LA = lipoatrophy; LH = lipohypertrophy.
*Adapted from Caron-Debarle et al.[2]













The only ART modification that has been shown to partially reverse SAT 
loss is switching from d4T or AZT to ABC or TDF.[11,12] One small study 
comparing the effect of three ABC substitution approaches over 48 weeks 
showed that fat mass in the arms and legs improved significantly (41% and 
52%, respectively) when d4T was replaced with ABC. There was, however, 
no improvement when treatment with a PI or NNRTI was stopped in 
favour of ABC.[13] On average, an estimated 400 - 500 g fat can be regained 
per year, but it is important to bear in mind that some patients may fail 
to demonstrate significant improvement due to possible exhaustion of the 
fat mesenchymal stem-cell pool. Furthermore, treatment modification 
may introduce risks associated with the new ART regimen, such as ABC 
hypersensitivity and TDF-associated nephrotoxicity; therefore, adequate 
monitoring should be in place. In light of the ongoing controversy 
regarding ABC and cardiovascular risk, ABC may best be avoided in 
patients with established cardiovascular disease (CVD). An alternative 
strategy is to switch to an NRTI-sparing regimen. This approach has 
also been shown to increase total limb fat by approximately 400 - 500 g 
per year, but has the disadvantage of possible increased dyslipidaemia 
(with all PIs except ATV). Furthermore, data on its long-term virological 
efficacy is limited.[8,14]
Lipohypertrophy
Weight gain is an expected consequence of successful ART. Weight 
reduction – or even better, avoidance of weight gain – through 
healthy diet and exercise may decrease VAT deposition and possibly 
improve insulin sensitivity and the lipid profile. There is, however, no 
information about the sufficient amount of diet and exercise needed to 
maintain this effect, and it may even aggravate LA. There are limited 
data on the effect of an ART regimen change on LH. In a trial of 201 
HIV-infected patients with abdominal fat accumulation and viral 
suppression, a switch from a twice-daily ritonavir-boosted PI regimen 
to once-daily ritonavir-boosted ATV led to a non-significant difference 
in limb fat loss at 48 weeks.[15] Some anecdotal data do, however, hint 
that ATV may have some effect: a very small case series of three patients 
described regression of central fat accumulation after nelfinavir (NFV) 



















Fig. 1. Metabolic impact of ART classes and individual drugs.[8] NNTRI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase 
inhibitor; PI = protease inhibitor.
Fig. 2. Metabolic consequences of lipodystrophy. VAT = visceral adipose tissue; 
SAT = subcutaneous adipose tissue; TNF = tumour necrosis factor; IL-6 = 
interleukin-6; FFAs = free fatty acids; NASH = Non-alcoholic steatohepatitis.












In a recent study by Lake et al.,[17] 39 virologically controlled women 
receiving TDF-FTC/ABC-3TC and either NNRTI- or PI-based ART, 
with LH, were randomised to immediate or delayed switch of the NNRTI 
or PI component to RAL. After 24 weeks, no statistically significant 
changes in VAT or SAT, anthropometrics, body mass index (BMI), 
glucose or C-reactive protein (CRP) were observed, but there were 
significant improvements in total and low-density lipoprotein (LDL) 
cholesterol (p=0.04).[17] There is therefore insufficient evidence to suggest 
that a change to the newer classes of drugs, such as integrase and entry 
inhibitors, may reverse LA or LH. The complexity of the data highlights 
the controversy of changing a treatment regimen for clinical and aesthetic 
reasons in the face of maximal virological suppression.
Novel treatment strategies
Lipoatrophy
Trials of the thiazolidinediones have shown that this drug class has very 
modest, if any, effect on lipoatrophic SAT. Although these drugs improve 
insulin sensitivity, they are known to induce harmful effects on blood 
lipids.[18] In a randomised controlled trial, pioglitazone was shown to 
increase the number and function of mitochondria and partially reverse 
peripheral fat loss in patients without thymidine NRTIs. This effect 
was, however, not noticeable to the patients.[19] Uridine, a pyrimidine 
nucleoside, has been postulated to protect fat cells from the adverse 
effects of thymidine analogues. After initial promising results, however, 
the drug failed to demonstrate improvement in limb fat in a subsequent 
multicentre clinical trial of 165 participants.[20] Pravastatin, a lipid-
lowering 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase 
inhibitor that is thought to have anti-inflammatory properties, was 
shown to partially reverse lipodystrophy in 33 hypercholesterolaemic 
men.[21] However, it failed to show a beneficial effect in a randomised 
trial of men who had discontinued thymidine NRTIs.[22]
Lipohypertrophy
Growth hormone (GH) has been shown to decrease VAT, but it may 
worsen subcutaneous LA and insulin resistance.[8] Tesamorelin, a GH-
releasing factor analogue, has been used to restore GH levels and has 
demonstrated a significant reduction in VAT hypertrophy. It has also been 
shown to improve the levels of TGs, HDL-C, adiponectin and insulin-
like growth factor 1 (IGF-1), although a small but statistically significant 
worsening of glucose profiles was also evident. Based on these data, the 
US Food and Drug Administration (FDA) approved tesamorelin for the 
treatment of excess abdominal fat in HIV-infected patients in November 
2010. The drug may only be used in patients without active malignancy 
and its widespread use is complicated by cost, the need for frequent 
monitoring of IGF-1 and glycosylated haemoglobin (HbA1c), and the lack 
of safety data beyond one year of use. Therapy should not be continued for 
longer than six months in the absence of a favourable treatment response, 
as assessed by a decrease in waist circumference.[23] Metformin is known 
to decrease VAT, especially in the presence of insulin resistance. It may, 
however, worsen subcutaneous LA and should not be used in patients 
with a low BMI. There are, however, not enough data to recommended 
its use in patients without diabetes mellitus (DM) at this stage. Anabolic 
steroids have not shown a beneficial response in the presence of normal 
blood testosterone levels and can also not be recommended at present. 
Overall, in light of the high cost of these treatments, limited data 
showing minimal improvement, an absence of clear long-term benefits 
and the possibility of new complications of the therapy, none of these 




Various surgical interventions have been proposed for the management 
of facial LA. There are, however, limited long-term data on the different 
approaches, and inadequate comparisons thereof. Polylactic acid 
(PLA) is a re-absorbable filler that is immunologically inert and causes 
only limited inflammation. Most patients report a good response 
after three to four injections. It is, however, prohibitively expensive. 
Hyaluronic acid and collagen produce equally favourable results, 
but the effects are less durable. Transplanting autologous harvested 
fat cells is becoming increasingly topical, but costs, the invasiveness 
of the technique and the requirement of general anaesthesia and 
hospitalisation limit its use.[24] Polyalkylamide (Bio-Alcamid) is a 
permanent filler and has been used with good effect, especially in 
cases of severe LA. Permanent fillers do not, however, have long-term 
safety data and have the disadvantage that, if LA progresses, then the 
edges of the filler may become visible. Conversely, if fat mass increases, 
the permanent filler may over-correct the original defect and hence 
become obvious and unsightly.[24]
Lipohypertrophy
Surgical interventions have been used for localised forms of LH, such as 
lipomas and buffalo humps. Options include standard surgical removal 
and liposuction. The duration of effect is, however, variable and up to 
half of the patients with dorsocervical disease experience a recurrence 
after 1 - 2 years. Surgery can also be considered when significant fat 
has accumulated around the breast tissue. Breast reduction surgery is 
invasive, requires anaesthesia and hospitilisation, and has a similar risk of 
fat return, especially if the patient cannot be established on a PI-sparing 
regimen. Surgery is not an option for patients with abdominal LH.
Screening for and managing 
metabolic complications 
Suggested approach
Prevention of HIV-related lipodystrophy is the best strategy and all HIV-
infected persons should be screened at regular intervals for a history 
of metabolic disease, dyslipidaemia, DM, hypertension and alteration 
of body composition (Table 2). Interventions to prevent CVD should 
vary in intensity according to a patient’s absolute risk of ischaemic heart 
disease. A comprehensive, multi-disciplinary approach is preferred. 
This should start with lifestyle interventions – counselling to stop 
smoking, modified diet and regular exercise – and be followed with 
a change of ART if needed, and the use of lipid-lowering medication 
in high-risk patients. The prevention and management of type 2 DM 
and hypertension should be in accordance with guidelines used in 
the general population. When pharmacological interventions are 
considered, care should be taken to avoid detrimental pharmacokinetic 
interactions, such as between statins and PIs.[24]
Conclusion
Lipodystrophy remains a challenge in the long-term management 
of HIV-infected patients receiving ART, and should be regarded as 
part of a more pervasive pathology. We recommend approaching the 
condition with targeted annual screening. In light of the absence of 










cost-effective measures to treat LA and LH, prevention remains the best 
option. Healthcare workers should be sensitised to the early detection 
of lipodystrophy in patients on thymidine-based ART regimens. 
Furthermore, affected patients should be switched to an appropriate 
regimen as soon as is feasible. There is currently no evidence to support 
the use of new-generation ARVs, except in patients with significant 
hypercholesterolaemia, where ATV and RAL may present better options. 
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Table 2. Suggested annual screening for 
metabolic complications
History • Family or personal history of CVD, 
DM or HT
• Concomitant treatment for DM, HT 
or dyslipidaemia
• Concomitant use of medication with 
risk for DM or dyslipidaemia
• Lifestyle: smoking, alcohol, exercise, 
diet
• Patient perception of change in body 
composition




• Clinical signs of lipodystrophy
• Blood pressure
• Cardiovascular risk assessment
Bloods • Lipids: fasting total cholesterol, TGs, 
LDL-C and HDL-C
• Glucose (fasting)
• Liver enzymes: ALT, AST, GGT, ALP
• Renal function: eGFR
Special investigations • ECG: men aged >40 years and women 
aged >50 years
CVD = cardiovascular disease; DM = diabetes mellitus; HT = hypertension; BMI = body 
mass index; TGs = triglycerides; LDL-C = low-density lipoprotein cholesterol; HDL-C = 
high-density lipoprotein cholesterol; ALT = alanine transaminase; AST = aspartate 
transaminase; GGT = gamma-glutamyl transpeptidase; ALP = alkaline phosphatase; 
eGFR = estimated glomerular filtration rate; ECG = electrocardiogram.
